Maya Martinez-Davis
Corporate Officer/Principal bei GSK PLC
Profil
Maya Martinez-Davis is currently the President-US Pharmaceuticals at GSK Plc.
Prior to this, she was the Independent Director at Mirati Therapeutics, Inc. from 2018 to 2024 and the President-Biopharma Latin America at Merck KGaA from 2016 to 2019.
She completed her undergraduate degree at St. Louis University and her graduate degree at Instituto de Empresa SL.
Aktive Positionen von Maya Martinez-Davis
| Unternehmen | Position | Beginn |
|---|---|---|
| GSK PLC | Corporate Officer/Principal | 01.01.2020 |
Ehemalige bekannte Positionen von Maya Martinez-Davis
| Unternehmen | Position | Ende |
|---|---|---|
| MIRATI THERAPEUTICS | Director/Board Member | 23.01.2024 |
| MERCK KGAA | Corporate Officer/Principal | 01.08.2019 |
Ausbildung von Maya Martinez-Davis
| St. Louis University | Undergraduate Degree |
| Instituto de Empresa SL | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| MERCK KGAA | Health Technology |
| GSK PLC | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
